These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 25669666

  • 1. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O, Boldorini R, Papalia E, Mezzapelle R, Baietto G, Roncon A, Casadio C.
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.
    Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, Lovato E, Hughes V, Fox-Rushby JA, Sharples LD, MesoVATS Collaborators.
    Lancet; 2014 Sep 20; 384(9948):1118-27. PubMed ID: 24942631
    [Abstract] [Full Text] [Related]

  • 3. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
    Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, Forgez P, Damotte D, Roche N, Régnard JF, Alifano M.
    J Thorac Cardiovasc Surg; 2013 May 20; 145(5):1305-11. PubMed ID: 23072703
    [Abstract] [Full Text] [Related]

  • 4. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT.
    Eur J Cardiothorac Surg; 2016 Jun 20; 49(6):1642-7. PubMed ID: 26802143
    [Abstract] [Full Text] [Related]

  • 5. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC.
    J Formos Med Assoc; 2019 Jan 20; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis.
    Al-Alao BS, Parissis H, Rychlik IJ, Graham A, McGuigan J.
    Asian Cardiovasc Thorac Ann; 2012 Aug 20; 20(4):443-9. PubMed ID: 22879552
    [Abstract] [Full Text] [Related]

  • 7. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA, Özmen Ö, Özdemirel TŞ, Erdoğan Y, Kaplan B, Kaplan T.
    Clin Respir J; 2018 Feb 20; 12(2):646-651. PubMed ID: 27768834
    [Abstract] [Full Text] [Related]

  • 8. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.
    Aelony Y, Yao JF.
    Respirology; 2005 Nov 20; 10(5):649-55. PubMed ID: 16268920
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W.
    Lancet Oncol; 2015 Dec 20; 16(16):1651-8. PubMed ID: 26538423
    [Abstract] [Full Text] [Related]

  • 10. Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.
    Maat A, Abdullah S, Schouten G, Cornelissen R, Bogers A, Mahtab E.
    Multimed Man Cardiothorac Surg; 2020 Jul 06; 2020():. PubMed ID: 32633902
    [Abstract] [Full Text] [Related]

  • 11. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y, Yamamoto Y, Otsuki T, Shinomiya M, Terada T, Fukuma S, Yamazaki S, Hirabayashi M, Nakano T, Fukuhara S.
    Jpn J Clin Oncol; 2015 Jun 06; 45(6):562-8. PubMed ID: 25838292
    [Abstract] [Full Text] [Related]

  • 12. Surgical resection of mesothelioma: an evidence-free practice.
    Lee YC.
    Lancet; 2014 Sep 20; 384(9948):1080-1. PubMed ID: 24942632
    [No Abstract] [Full Text] [Related]

  • 13. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.
    Br J Cancer; 2014 Oct 28; 111(9):1860-9. PubMed ID: 25188323
    [Abstract] [Full Text] [Related]

  • 14. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
    Kapeles M, Gensheimer MF, Mart DA, Sottero TL, Kusano AS, Truong A, Farjah F, Laramore GE, Stelzer KJ, Patel SA.
    Am J Clin Oncol; 2018 Jan 28; 41(1):30-35. PubMed ID: 26353120
    [Abstract] [Full Text] [Related]

  • 15. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R, Fiordoliva I, De Lisa M, Ballatore Z, Caramanti M, Morgese F, Savini A, Rinaldi S, Torniai M, Tiberi M, Ferrini C, Onofri A, Cascinu S.
    Tumori; 2016 Jan 28; 102(2):190-5. PubMed ID: 26893272
    [Abstract] [Full Text] [Related]

  • 16. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H, Asami K, Hirashima T, Okamoto N, Yamadori T, Tamiya M, Morishita N, Shiroyama T, Takeoka S, Osa A, Azuma Y, Okishio K, Kawaguchi T, Atagi S, Kawase I.
    Lung; 2014 Feb 28; 192(1):191-5. PubMed ID: 24141556
    [Abstract] [Full Text] [Related]

  • 17. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
    Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.
    Cancer Med; 2017 Oct 28; 6(10):2287-2296. PubMed ID: 28941158
    [Abstract] [Full Text] [Related]

  • 18. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.
    Lancet Oncol; 2017 Oct 28; 18(10):1386-1396. PubMed ID: 28870611
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
    Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M.
    Br J Cancer; 2014 Jul 15; 111(2):220-6. PubMed ID: 24918816
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.
    Habal P, Omran N, Jankovicova K, Krejsek J, Mandak J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun 15; 159(2):234-41. PubMed ID: 25059234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.